Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FTSE 250 movers: CSR jumps as chip sales impress

Thu, 29th Oct 2009 12:11

CSR, which makes chips for Bluetooth and Global Positioning System (GPS) devices, is sharply higher after third quarter results were better than expected.Pre-tax profits for the period totalled $10.7m compared with a $30.8m over the same period the previous year. Revenues climbed to $219.9m from $205.5m. Bluetooth accounted for $150.4m, GPS for $59.5m.At the time of its second quarter results, CSR issued third quarter guidance of $195m to $215m for revenue. The median forecast of investment analysts' revenue forecasts was $208m.Qinetiq climbs after saying the boss of defence technology group QinetiQ, Graham Love, is being replaced by the former chief of banknote printer De La Rue, Leo Quinn, after eight years at the company.Investment management firm Evolution Group is going well after saying it expects to beat full year profit forecasts this year on the back of strong trading across all of its divisions. Revenues from the Investment Banking arm in the second half of 2009 will be at least double those seen in the first half, reflecting the increased corporate activity.Elsewhere in finance, Fund manager Henderson said assets under management increased 9% to £57.7bn in the third quarter to 30 September 2009 as market conditions continue to improve.National Express is sharply lower after the hard-up bus and train group said it has ended all takeover discussions with rival Stagecoach in order to focus on completing an equity fundraising by the end of this year.Shares in Yell fall back after the cash-strapped Yellow Pages directory publisher Yell Group again extended the deadline for its refinancing. The company, which is looking to restructure £3.8bn of debt, extended the deadline for the third time this week after last night's cut-off passed without success.FTSE 250 - RisersCSR (CSR) 446.60p +11.07%QinetiQ Group (QQ.) 154.80p +8.33%Taylor Wimpey (TW.) 37.77p +5.77%Aquarius Platinum Ltd. (AQP) 274.00p +5.71%Redrow (RDW) 139.80p +5.43%Evolution Group (EVG) 158.50p +4.55%Victrex (VCT) 784.50p +4.32%Barratt Developments (BDEV) 135.30p +4.24%BlueBay Asset Management (BBAY) 368.40p +3.98%Tomkins (TOMK) 162.60p +3.90%FTSE 250 - FallersNational Express Group (NEX) 328.10p -10.01%Laird (LRD) 163.20p -9.33%PartyGaming (PRTY) 221.50p -5.54%Henderson Group (HGG) 127.40p -4.64%PayPoint (PAY) 448.50p -4.17%Melrose Resources (MRS) 357.60p -2.85%Yell Group (YELL) 45.04p -2.81%Imagination Technologies (IMG) 202.50p -2.64%Debenhams (DEB) 77.50p -2.52%PV Crystalox Solar (PVCS) 65.55p -2.16%
More News
20 Sep 2021 14:50

IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells

IN BRIEF: Evgen Pharma's SFX-01 effective on tumour cells

Read more
2 Sep 2021 11:56

IN BRIEF: Evgen SFX-01 granted orphan drug designation by US FDA

IN BRIEF: Evgen SFX-01 granted orphan drug designation by US FDA

Read more
13 Jul 2021 15:36

Evgen pleased with preclinical data on SFX-01

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced preclinical data demonstrating that 'SFX-01' was effective in in-vitro models of certain blood cancers on Tuesday.

Read more
13 Jul 2021 14:09

IN BRIEF: Evgen Pharma files brain tumour treatment request with FDA

IN BRIEF: Evgen Pharma files brain tumour treatment request with FDA

Read more
13 Jul 2021 11:25

IN BRIEF: Evgen Pharma encouraged by early data for SFX-01

IN BRIEF: Evgen Pharma encouraged by early data for SFX-01

Read more
13 Jul 2021 11:20

AIM WINNERS & LOSERS: Star Phoenix wins new deal; Ebiquity revenue up

AIM WINNERS & LOSERS: Star Phoenix wins new deal; Ebiquity revenue up

Read more
9 Jul 2021 11:51

Evgen Pharma halts trial as SFX-01 drug fails to help Covid patients

Evgen Pharma halts trial as SFX-01 drug fails to help Covid patients

Read more
9 Jul 2021 10:52

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

Read more
9 Jul 2021 10:33

Evgen 'surprised and disappointed' by findings in SFX-01 trial

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the results of the interim safety and futility assessment readout of the first 100 patients treated in the 'STAR' Covid-19 trial of its lead asset, 'SFX-01', on Friday.

Read more
6 Jul 2021 16:10

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
15 Jun 2021 14:42

TRADING UPDATES: GB Group rebuilds dividend; IPF ups 2021 profit view

TRADING UPDATES: GB Group rebuilds dividend; IPF ups 2021 profit view

Read more
14 Jun 2021 13:19

TRADING UPDATES: Synectics loss narrows; Active Energy loss widens

TRADING UPDATES: Synectics loss narrows; Active Energy loss widens

Read more
14 Jun 2021 11:00

Evgen upbeat on new data on potential breast cancer treatment

(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced new preclinical data on Monday, which showed 'SFX-01' could be of benefit to metastatic breast cancer (mBC) patients who had become resistant to CDK4/6 inhibitors.

Read more
26 Apr 2021 13:02

IN BRIEF: Evgen Pharma appoints Huw Jones as chief medical officer

IN BRIEF: Evgen Pharma appoints Huw Jones as chief medical officer

Read more
7 Apr 2021 16:22

IN BRIEF: Evgen Pharma notes publication on sulforaphane in Covid-19

IN BRIEF: Evgen Pharma notes publication on sulforaphane in Covid-19

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.